Clinical trial

Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer After Ovarian Hyperstimulation (Administration of rFSH or HP-hMG Alone or Co-administration of rFSH and HP-hMG)

Name

LG-IMHOS001

Description

A multicenter, retrospective cohort observational study to evaluate the effectiveness and safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG)

Trial arms

Trial start

2021-09-14

Estimated PCD

2022-12-31

Trial end

2023-06-30

Status

Completed

Treatment

rFSH

rFSH or HP-hMG or rFSH and HP-hMG

Arms:

fresh embryo, frozen embryo

Other names:

HP-hMG, rFSH and HP-hMG

Size

1166

Primary endpoint

Number of Oocytes

average of 14 days

Eligibility criteria

Inclusion Criteria: * First IVF-ET cycle patients Exclusion Criteria: Poor ovarian responder - At least two of the following three features must be present: (i) Advanced maternal age (≥ 40 years) or any other risk factor for Poor ovarian response (POR); (ii) A previous POR (≤ 3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC \< 5-7 follicles or AMH \< 0.5-1.1 ng/mL)

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 1166, 'type': 'ACTUAL'}}

Updated at

2023-08-23

1 organization

1 product

2 indications

Organization

Product

Indication

Indication